JPRN-jRCT2080222701未知1 期
Clinical Pharmacology study for AS-3201 in renal impairment subjects
Sumitomo Dainippon Pharmaceuticals Co., Ltd.0 个研究点目标入组 24 人开始时间: 2014年12月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •-Subjects who provided written voluntary consent to participate in the study
- •-eGFR < 60 mL/min/1.73 m2 (renal impairment subjects)
- •-45.0 kg =< body weight =< 80.0 kg and 18.5 kg/m2 =< BMI <30.0 kg/m2
排除标准
- •-Subjects who have a serious complication
- •-Subjects who received an AS-3201
研究者
相似试验
已完成
1 期
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)Renal ImpairmentType 2 Diabetes MellitusNCT01948986Merck Sharp & Dohme LLC36
已完成
1 期
A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02Impaired Renal FunctionNCT03776539Eloxx Pharmaceuticals, Inc.24
已完成
不适用
Evaluation of renal effect of NSAIDhealth volunteerJPRN-UMIN000002278kawasaki medical school20
已完成
1 期
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy VolunteersRenal ImpairmentNCT01578928Novartis Pharmaceuticals50
已完成
3 期
A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal ImpairmentType 2 Diabetes MellitusNCT01316094Astellas Pharma Inc165